University of Adelaide researchers are playing a leading role in the human trials of Australia’s first needle-free, gene-based COVID-19 vaccine.
The extended phase 1 human trial will evaluate a COVID-19 gene-based vaccine called COVIGEN, developed by BioNet and Technovalia.
The study is led by Professor Nicholas Wood from the University of Sydney and the Vax4COVID Alliance, which includes co-investigator Professor Helen Marshall, from the Robinson Research Institute, University of Adelaide and Women’s and Children’s Hospital, Adelaide.
“The COVIGEN DNA-based vaccine is one of only a handful to enter into clinical trials worldwide, and the first in Australia,” Professor Marshall says.
